1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2022, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 3, 1, 13 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hypertrophic Cardiomyopathy - Overview
- Hypertrophic Cardiomyopathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hypertrophic Cardiomyopathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development
- Algomedix Inc
- BioMarin Pharmaceutical Inc
- Bristol-Myers Squibb Co
- C&C BioPharma LLC
- Cardior Pharmaceuticals GmbH
- Celltrion Inc
- Cytokinetics Inc
- DiNAQOR AG
- Edgewise Therapeutics Inc
- Genome Biologics UG
- Haya Therapeutics SA
- Igia Pharmaceuticals Inc
- Imbria Pharmaceuticals Inc
- Invivosciences Inc
- Jaan Biotherapeutics LLC
- Lead Discovery Center GmbH
- LEXEO Therapeutics LLC
- Novartis AG
- Saliogen Therapeutics Inc
- Tenaya Therapeutics Inc
- Toa Eiyo Ltd
- Hypertrophic Cardiomyopathy - Drug Profiles
- Product Description
- Mechanism Of Action
- History of Events
- 8-MI - Drug Profile
- Product Description
- Mechanism Of Action
- aficamten - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CDR-348T - Drug Profile
- Product Description
- Mechanism Of Action
- CDR-641L - Drug Profile
- Product Description
- Mechanism Of Action
- CK-271 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CTG-20 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dasatinib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DINA-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DINA-008 - Drug Profile
- Product Description
- Mechanism Of Action
- DINA-009 - Drug Profile
- Product Description
- Mechanism Of Action
- DINA-010 - Drug Profile
- Product Description
- Mechanism Of Action
- DINA-011 - Drug Profile
- Product Description
- Mechanism Of Action
- Drugs to Inhibit PDE3A1 for Hypertrophic Cardiomyopathy - Drug Profile
- Product Description
- Mechanism Of Action
- EDG-002 - Drug Profile
- Product Description
- Mechanism Of Action
- GEN-387 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene therapy for Hypertrophic Cardiomyopathy - Drug Profile
- Product Description
- Mechanism Of Action
- GRK5 - Drug Profile
- Product Description
- Mechanism Of Action
- HTX-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Hypertrophy Cardiomyopathy - Drug Profile
- Product Description
- Mechanism Of Action
- JN-210 - Drug Profile
- Product Description
- Mechanism Of Action
- LX-2022 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mavacamten - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MYK-224 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MYK-581 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ninerafaxstat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Peptides to Agonize MFN2 for Charcot Marie Tooth Disease Type IIA and Hypertrophic Cardiomyopathy - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Cardiac Hypertrophy - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Hypertrophic Cardiomyopathy - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TN-201 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TRPC6 ANTAGONIST - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TY-0305 - Drug Profile
- Product Description
- Mechanism Of Action
- Hypertrophic Cardiomyopathy - Dormant Projects
- Hypertrophic Cardiomyopathy - Product Development Milestones
- Featured News & Press Releases
- Aug 10, 2022: LianBio completes enrollment in pivotal phase 3 EXPLORER-CN trial of mavacamten in Chinese obstructive hypertrophic cardiomyopathy patients
- Jun 13, 2022: Cytokinetics announces additional data from REDWOOD-HCM presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
- Jun 13, 2022: Cytokinetics announces additional results from REDWOOD-HCM to be presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
- May 23, 2022: Cytokinetics announces data from REDWOOD-HCM OLE presented as late breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
- May 09, 2022: LianBio Completes phase 1 pharmacokinetic study of mavacamten in Healthy Chinese Volunteers
- Apr 29, 2022: BMS receives US FDA approval for Camzyos to treat cardiomyopathy
- Apr 04, 2022: BMS’ mavacamten boosts cardiovascular outcomes in obstructive HCM study
- Apr 02, 2022: Mavacamten demonstrated significant reduction in need for septal reduction therapy in symptomatic obstructive HCM patients in phase 3 VALOR trial
- Apr 02, 2022: Cytokinetics announces results from cohort 3 of Redwood-HCM presented at American College of Cardiology 71st Annual Scientific Session
- Mar 24, 2022: Cytokinetics announces presentations on aficamten at the American College of Cardiology 71st Annual Scientific Session & Expo
- Mar 21, 2022: Bristol Myers Squibb to demonstrate the strength of its growing cardiovascular portfolio at the American College of Cardiology’s 71st annual scientific session
- Mar 02, 2022: Cytokinetics announces Cohort 4 of REDWOOD-HCM is open to enrollment
- Feb 23, 2022: Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy
- Feb 16, 2022: Jixing announces receipt of breakthrough therapy designation for AFICAMTEN in CHINA
- Feb 16, 2022: Bristol Myers Squibb announces positive topline results from phase 3 VALOR-HCM trial, evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hypertrophic Cardiomyopathy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Algomedix Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by BioMarin Pharmaceutical Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Bristol-Myers Squibb Co, 2022
- Hypertrophic Cardiomyopathy - Pipeline by C&C BioPharma LLC, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Cardior Pharmaceuticals GmbH, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Celltrion Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Cytokinetics Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by DiNAQOR AG, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Edgewise Therapeutics Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Genome Biologics UG, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Haya Therapeutics SA, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Igia Pharmaceuticals Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Imbria Pharmaceuticals Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Invivosciences Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Jaan Biotherapeutics LLC, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, 2022
- Hypertrophic Cardiomyopathy - Pipeline by LEXEO Therapeutics LLC, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Novartis AG, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Saliogen Therapeutics Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Tenaya Therapeutics Inc, 2022
- Hypertrophic Cardiomyopathy - Pipeline by Toa Eiyo Ltd, 2022
- Hypertrophic Cardiomyopathy - Dormant Projects, 2022
- Number of Products under Development for Hypertrophic Cardiomyopathy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Algomedix Inc
- BioMarin Pharmaceutical Inc
- Bristol-Myers Squibb Co
- C&C BioPharma LLC
- Cardior Pharmaceuticals GmbH
- Celltrion Inc
- Cytokinetics Inc
- DiNAQOR AG
- Edgewise Therapeutics Inc
- Genome Biologics UG
- Haya Therapeutics SA
- Igia Pharmaceuticals Inc
- Imbria Pharmaceuticals Inc
- Invivosciences Inc
- Jaan Biotherapeutics LLC
- Lead Discovery Center GmbH
- LEXEO Therapeutics LLC
- Novartis AG
- Saliogen Therapeutics Inc
- Tenaya Therapeutics Inc
- Toa Eiyo Ltd
